Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
Geraldine O'Sullivan CoyneShivaani KummarJames S HuKristen N GanjooWarren A ChowKhanh T DoJennifer ZlottAshley BrunsLawrence V RubinsteinJared C FosterLamin JuwaraRobert MeehanRichard L PiekarzHoward StreicherElad SharonNaoko TakebeAndrea Regier VothDonald P BottaroRene CostelloJohn J WrightJames H DoroshowHelen X ChenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Cabozantinib single-agent antitumor activity was observed in patients with selected STS histologic subtypes (alveolar soft-part sarcoma, undifferentiated pleomorphic sarcoma, extraskeletal myxoid chondrosarcoma, and leiomyosarcoma) highlighting the biomolecular diversity of STS.